PTC Therapeutics and the billion-dollar edit

A cell can have the right gene and still make too little of the protein it needs. Between genetic instructions and a working protein sits RNA, a molecule that must be processed and read. PTC Therapeutics began with a proposition: this middle stage offered places where a medicine could intervene. The company’s name, post-transcriptional control, practically gives away the research plan.

• The work: medicines for rare genetic, neurological and metabolic disorders.
• The edge: RNA expertise, supplemented by acquired medicines and gene therapy.
• The tension: successful products and valuable licenses alongside costly failures of clinical proof.

Founded in 1998, PTC turned that proposition into a business that now sells medicines internationally and licenses research to larger pharmaceutical companies. But its history is more interesting than a straight line from laboratory insight to prescription. It asks a question familiar far beyond biotechnology: when an idea disappoints, which part do you abandon?

The instructions after the instructions

Stuart Peltz, Allan Jacobson and Tariq Rana were among PTC’s founders. The early company explored RNA biology and the processes controlling protein production. Peltz remained chief executive for roughly 25 years, before Matthew Klein succeeded him in March 2023. The institutional patience is striking. A research premise can survive far longer than the financing round that first makes it possible.

One important capability is small-molecule splicing modulation. Before certain RNA instructions are used, segments are removed and the remaining material joined. A drug can influence that assembly. Evrysdi, developed with Roche and the SMA Foundation, changes SMN2 splicing to increase functional survival motor neuron protein in spinal muscular atrophy. Its initial US approval arrived in 2020.

Votoplam, previously called PTC518, pursues a different outcome: lowering huntingtin production for Huntington’s disease. In December 2024, Novartis agreed to license the program. The deal closed in January 2025 with $1 billion upfront. That payment purchased rights to an investigational program, with substantial work still ahead. By July 2026, enrollment in the Phase 3 INVEST-HD study was ongoing.

The trial gets a vote

PTC’s earlier ataluren program tried to address premature stop signals that interrupt protein production. The biological logic was attractive. Its cystic fibrosis development ended in 2017 after a Phase 3 trial failed to show significant improvement in lung function or sufficient reduction in pulmonary exacerbations. A plausible explanation of disease had not delivered the required patient benefit.

Ataluren’s Duchenne history proved longer and more contentious. Sold as Translarna, it received conditional European authorization in 2014. In March 2025, the European Commission declined to renew that authorization after effectiveness was not confirmed. In February 2026, PTC withdrew its US application following FDA feedback. Conditional approval had created an obligation to resolve uncertainty; years on the market did not remove it.

“Challenge. Adapt. Repeat.”

One of PTC’s published cultural expectations

Another candidate, vatiquinone for Friedreich’s ataxia, received an FDA complete response letter in August 2025 because substantial efficacy evidence had not been demonstrated. PTC subsequently planned another study. These episodes supply a useful distinction: discontinuing one indication, seeking more evidence in another and retaining a scientific platform are different decisions. Persistence needs a specific object.

A medicine still needs a route to the patient

PTC also buys capabilities. Its 2020 acquisition of Censa brought sepiapterin, now Sephience, into the portfolio. FDA approved the oral medicine in July 2025 for patients aged one month and older with sepiapterin-responsive phenylketonuria, alongside a phenylalanine-restricted diet. PKU impairs the handling of phenylalanine, an amino acid whose accumulation can harm the brain. Treatment becomes part of everyday eating.

For patients and clinicians, Sephience adds an option to a field that already includes sapropterin and BioMarin’s Palynziq. Eligibility, response, monitoring and administration matter more than a simple league table. PTC reported 1,647 commercial Sephience patients worldwide at June 30, 2026. In a rare disorder, reaching that population requires specialist relationships and access arrangements across countries.

Then consider Kebilidi, PTC’s AADC-deficiency gene therapy, known as Upstaza in Europe. It is infused directly into the brain through a surgical procedure. US accelerated approval came in November 2024, with confirmatory evidence obligations. An oral powder and a neurosurgical infusion belong to radically different delivery systems. PTC’s expertise must extend beyond discovery into the practical machinery of treatment.

Read the revenue label

The financing is equally varied. PTC reported $1.731 billion in total revenue for 2025, including $998.4 million of collaboration and license revenue related to Novartis. Net product revenue was $586.7 million. Royalties and a negative France adjustment complete the arithmetic. Calling the total “drug sales” would obscure what actually happened.

PTC spent $455.2 million on research and development that year. This is one year’s expense, not the lifetime cost of discovering its medicines. The Novartis agreement also includes up to $1.9 billion in contingent milestones, US profit sharing and royalties outside the US. Those future possibilities depend on events that have not all occurred.

Cash can also come from selling future income. In December 2025, PTC sold its remaining Evrysdi royalty interest to Royalty Pharma for $240 million upfront, plus possible milestones. The exchange is straightforward: money now, less participation later. Readers evaluating the company should follow both the medicine and who owns its future economics.

Keep the capability. Reconsider the bet.

PTC made another bet in September 2026, acquiring Sangamo’s investigational Fabry gene therapy ST-920 through a bankruptcy sale. The price was $111 million upfront, with up to $100 million in regulatory milestones. Completion of its rolling FDA submission was expected in the fourth quarter. Acquisition transferred the opportunity and the remaining obligations together.

The transferable lesson is to preserve useful expertise while revisiting individual commitments, and to choose partners for work they can carry. That approach needs cash, credible evidence and a workable route to patients. Without those conditions, another trial or transaction simply extends the bill. PTC’s history makes the question concrete: what, exactly, has earned the right to continue?